RENE.L Regulatory News (RENE)

ReNeuron Group plc

("ReNeuron" or the "Company" or the "Group")

Directorate and Executive Changes

Appointment of Chief Financial Officer and Chief Business Officer

ReNeuron Group plc (AIM: RENE), a UK-based leader in stem cell derived exosome technologies, announces the appointment of John Hawkins, ACA, as Chief Financial Officer ('CFO') and ReNeuron Board member with immediate effect. The Group is also pleased to announce that Simon Dew will be joining the Executive Team as Chief Business Officer ('CBO').

Mr. Hawkins joined ReNeuron in October 2014 as Financial Controller and was also appointed Company Secretary in June 2021. Mr Hawkins is an experienced finance professional with a breadth of experience gained within a variety of businesses, from large PLCs to family-owned SMEs. Mr Hawkins graduated from university with a 1st class honours degree in industrial chemistry and started his career with KPMG, where he qualified as a Chartered Accountant and worked for the initial part of his career.

Mr. Dew is a senior healthcare executive with extensive experience in Business Development and Corporate Strategy. His career spans working at SmithKline Beecham, IQVIA, Astellas Pharma, Gyroscope and more recently exosomes company Evox Therapeutics, where he was responsible for leading two transformational partnership deals with global pharmaceutical companies.

Additionally, the Group is making changes to the Executive team. With immediate effect, Dr. Randolph Corteling assumes the role of Chief Scientific Officer ('CSO') with Prof. Stefano Pluchino moving to the role of Chair of the Scientific Advisory Board, continuing to combine working with ReNeuron and his academic work in Exosomes and Regenerative Neuroimmunology at the University of Cambridge. Suzanne Hancock, currently Head of Operations, who has worked with the Group since 2017, moves to the position of Chief Operations Officer ('COO').

Iain Ross, Non-Executive Chairman, commented "I am delighted to announce John Hawkins' appointment as CFO and a director of the Company and also to welcome Simon Dew as member of the Executive team. I believe under Catherine's leadership we have a strong executive team in place to execute our plans." 

Catherine Isted, Chief Executive Officer, commented: "I am delighted John has accepted the position of CFO. He has been a key part of the team redefining the operational and strategic focus of the Group and his extensive knowledge of the business and tireless work ethic have been invaluable especially in this period of transition.

"The appointment of Simon Dew as CBO will be a key role in the new ReNeuron Executive team to maximise the opportunity we see ahead of us in the field and to accelerate our partnership opportunities. We are delighted to have been able to attract a candidate of such high calibre and experience, especially in the field of exosomes, to join the Group.

"With the other Executive changes announced today, I believe we have the right team in place to deliver on the full potential that our customisable Exosomes platform has to offer to biotech and pharma partners and ultimately deliver value to our shareholders as we build ReNeuron into the sustainable growing and commercially validated business we know it can become."

The following information is disclosed in respect of John Hawkins pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for Companies.

The names of all companies and partnerships of which John Michael Hawkins, aged 56, has been a director or partner at any time in the previous five years are set out below:

John Hawkins holds options over 340,000 ordinary shares of ReNeuron. Save as set out in this announcement, there are no further details to be disclosed under Rule 17 or Schedule 2(g) of the AIM Rules for Companies in respect of John Hawkins.

ENDS

The person responsible for arranging for the release of this announcement on behalf of the Company is

Catherine Isted, Chief Executive Officer.

Contacts:

About ReNeuron

ReNeuron is a UK based leader in Proprietary Stem Cell derived Exosome Technologies company, harnessing its unique stem cell technologies to develop 'off the shelf' treatments for diseases with significant unmet needs.

ReNeuron's stem cell derived proprietary Exosome Technology platform offers a delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins, small molecules and genes. The Group has a growing number of partner collaborations with Global Pharma, Biotech and academic partners in this fast-expanding area of scientific and commercial interest. ReNeuron also has the ability, through its conditionally immortalised induced pluripotent stem cell (iPSC) platform, to make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.

The Group has out-licenced its CTX Programme for stroke disability and hRPC programme in retinitis pigmentosa to Fosun in China and is looking to out-licence both these programmes in other territories.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com